The specific criteria for inclusion and exclusion of relevant studies in terms of PI(E)COS (Population, Intervention/Exposure, Comparison, Outcomes, and Study design) are provided in Table 1
Sources Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company July 23, 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) National Library of Medicine April 13, 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) National Library of Medicine May 22, 2026,
Immune System Support Your immune system relies on glutathione to function properly
Determine Qualification: Based on your body mass index (BMI) and any underlying medical issues, your healthcare practitioner will determine whether semaglutide is a good fit for you
